Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

pennant group inc - PNTG

PNTG

Close Chg Chg %
42.23 -0.35 -0.83%

Closed Market

41.88

-0.35 (0.83%)

Volume: 233.32K

Last Updated:

Oct 23, 2026, 4:00 PM EDT

Trade Now

Company Overview: pennant group inc - PNTG

PNTG Key Data

Open

$41.78

 Day Range

41.73 - 42.25

52 Week Range

22.26 - 42.74

 Market Cap

$1.43B

Shares Outstanding

34.93M

 Public Float

33.16M

Beta

1.25

 Rev. Per Employee

N/A

P/E Ratio

45.25

 EPS

$0.93

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

309.86K

  

PNTG Performance

1 Week
 
 0.02%
 
1 Month
 
 2.72%
 
3 Months
 
 1.75%
 
1 Year
 
 65.93%
 
5 Years
 
 63.79%
 

PNTG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About pennant group inc - PNTG

The Pennant Group, Inc. is a holding company, which engages in the provision of healthcare services to patients of all ages. It operates through the Home Health and Hospice Services, and Senior Living Services segments. The Home Health and Hospice Services segment provides a combination of clinical care services such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services. The Senior Living Services segment deals with assisted and independent living and memory care businesses. The company was founded on January 24, 2019 and is headquartered in Eagle, ID.

PNTG At a Glance

The Pennant Group, Inc.
1675 East Riverside Drive
Eagle, Idaho 83616
Phone 1-208-506-6100 Revenue 947.71M
Industry Medical/Nursing Services Net Income 29.58M
Sector Health Services 2025 Sales Growth 36.313%
Fiscal Year-end 12 / 2026 Employees 9,700
View SEC Filings

PNTG Valuation

P/E Current 45.253
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 33.612
Price to Sales Ratio 1.049
Price to Book Ratio 2.931
Price to Cash Flow Ratio 20.59
Enterprise Value to EBITDA 22.528
Enterprise Value to Sales 1.56
Total Debt to Enterprise Value 0.311

PNTG Efficiency

Revenue/Employee 97,701.546
Income Per Employee 3,049.278
Receivables Turnover 7.698
Total Asset Turnover 1.093

PNTG Liquidity

Current Ratio 1.137
Quick Ratio 1.137
Cash Ratio 0.116

PNTG Profitability

Gross Margin 12.922
Operating Margin 6.025
Pretax Margin 4.815
Net Margin 3.121
Return on Assets 3.41
Return on Equity 9.452
Return on Total Capital 3.733
Return on Invested Capital 4.522

PNTG Capital Structure

Total Debt to Total Equity 138.25
Total Debt to Total Capital 58.027
Total Debt to Total Assets 47.494
Long-Term Debt to Equity 128.98
Long-Term Debt to Total Capital 54.137
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pennant Group Inc - PNTG

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
473.24M 544.89M 695.24M 947.71M
Sales Growth
+7.63% +15.14% +27.59% +36.31%
Cost of Goods Sold (COGS) incl D&A
419.56M 482.99M 607.60M 825.24M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.90M 5.13M 6.12M 8.54M
Depreciation
4.86M 5.12M 6.12M 8.54M
Amortization of Intangibles
- - 44.00K 10.00K
-
COGS Growth
+5.22% +15.12% +25.80% +35.82%
Gross Income
53.69M 61.91M 87.64M 122.47M
Gross Income Growth
+31.09% +15.31% +41.57% +39.73%
Gross Profit Margin
+11.34% +11.36% +12.61% +12.92%
2022 2023 2024 2025 5-year trend
SG&A Expense
33.17M 36.19M 49.50M 65.37M
Research & Development
- - - -
-
Other SG&A
33.17M 36.19M 49.50M 65.37M
SGA Growth
-2.92% +9.10% +36.78% +32.06%
Other Operating Expense
- - - -
-
Unusual Expense
808.00K 476.00K 708.00K 6.21M
EBIT after Unusual Expense
19.70M 25.24M 37.43M 50.89M
Non Operating Income/Expense
(7.00M) 269.00K 889.00K 1.42M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
3.82M 5.92M 6.96M 6.68M
Interest Expense Growth
+96.60% +55.24% +17.42% -4.00%
Gross Interest Expense
3.82M 5.92M 6.96M 6.68M
Interest Capitalized
- - - -
-
Pretax Income
8.89M 19.58M 31.37M 45.63M
Pretax Income Growth
+225.71% +120.24% +60.17% +45.47%
Pretax Margin
+1.88% +3.59% +4.51% +4.81%
Income Tax
1.65M 5.67M 7.03M 11.87M
Income Tax - Current - Domestic
(47.00K) 1.67M 8.21M 14.06M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
1.70M 4.00M (1.19M) (2.19M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
7.24M 13.91M 24.34M 33.76M
Minority Interest Expense
600.00K 531.00K 1.78M 4.19M
Net Income
6.64M 13.38M 22.56M 29.58M
Net Income Growth
+146.40% +101.40% +68.61% +31.11%
Net Margin Growth
+1.40% +2.46% +3.24% +3.12%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
6.64M 13.38M 22.56M 29.58M
Preferred Dividends
- - - -
-
Net Income Available to Common
6.64M 13.38M 22.56M 29.58M
EPS (Basic)
0.2286 0.448 0.7232 0.8558
EPS (Basic) Growth
+140.89% +95.98% +61.43% +18.34%
Basic Shares Outstanding
29.06M 29.86M 31.19M 34.56M
EPS (Diluted)
0.2203 0.4431 0.705 0.8375
EPS (Diluted) Growth
+150.34% +101.13% +59.11% +18.79%
Diluted Shares Outstanding
30.16M 30.19M 32.00M 35.32M
EBITDA
25.41M 30.84M 44.26M 65.64M
EBITDA Growth
+119.69% +21.38% +43.49% +48.29%
EBITDA Margin
+5.37% +5.66% +6.37% +6.93%

Snapshot

Average Recommendation BUY Average Target Price 46.833
Number of Ratings 7 Current Quarters Estimate 0.366
FY Report Date 12 / 2026 Current Year's Estimate 1.401
Last Quarter’s Earnings 0.36 Median PE on CY Estimate N/A
Year Ago Earnings 1.18 Next Fiscal Year Estimate 1.587
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 5 7 7
Mean Estimate 0.37 0.36 1.40 1.59
High Estimates 0.38 0.38 1.42 1.62
Low Estimate 0.34 0.33 1.38 1.53
Coefficient of Variance 4.11 5.71 1.12 1.81

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Pennant Group Inc - PNTG

Date Name Shares Transaction Value
Oct 20, 2026 Scott E. Lamb Director 61,335 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 20, 2026 Barry Morgan Smith Director 104,399 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 20, 2026 Christopher R. Christensen Director 147,891 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 20, 2026 John G. Nackel Director 176,465 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 20, 2026 Suzanne D. Snapper Director 232,264 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 20, 2026 Stephen M. R. Covey Director 45,950 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 20, 2026 Gregory K. Morris Director 39,200 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Brent J. Guerisoli Chief Executive Officer 102,030 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Brent J. Guerisoli Chief Executive Officer 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 John J. Gochnour Chief Operating Officer 152,815 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 John J. Gochnour Chief Operating Officer 41,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Kirk S. Cheney EVP, GC and Corp Secy 21,005 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Kirk S. Cheney EVP, GC and Corp Secy 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Lynette B. Walbom Chief Financial Officer 16,955 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Lynette B. Walbom Chief Financial Officer 34,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Jason P. Steik Chief Clinical Officer 26,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Pennant Group Inc in the News